Wonderful overlooked fact about Obamacare--it will curtail mandatory alternative medicine coverage!

[pnwmom]

51. They can. Bastyr University has been actively engaged in research for years, in partnership

with organizations like the NIH and University of Washington.

http://www.bastyr.edu/research/studies

Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study NIH/NCCAM (R01)

Status: Ongoing
Study area: Oncology
Principal investigator: Leanna Standish
Project period: August 1, 2010, to March 31, 2015
The purpose of this five-year project is to conduct a prospective matched controlled outcomes study that describes physician directed integrated oncology therapies and their effects on breast cancer patients' quality of life, cancer recurrence and survival rates for those who receive integrated o
Bastyr/UW Oncomycology Translational Research Center

Status: Ongoing
Study area: Oncology
Principal investigator: NIH/NCCAM (U19) Partnership with University of Washington
Co-investigator(s): Leanna Standish, Mary L. (Nora) Disis
Project period: September 29, 2010, to August 31, 2014
The Bastyr University/University of Washington PCCTR Oncomycology Research Center will investigate the immunologic and antitumor effects of Trametes versicolor (Tv) a traditional Chinese medicine medicinal mushroom, for use in the treatment of prostate cancer and breast cancer patients in the U.S
PSK as Neoadjuvant Therapy for Locally Advanced Breast Cancer Principal

Status: Ongoing
Study area: Oncology
Principal investigator: Hailing Lu (University of Washington)
Co-investigator(s): Cynthia Wenner, PhD
Project period: April 2010 – March 2014
Clinical management of locally advanced breast cancer remains challenging as patients have a high risk for relapse, especially those patients whose tumors over-express the HER-2/neu (HER2+) oncogenic protein and have limited expression of estrogen receptors (ER-).
Intranasal Glutathione in Parkinson's Disease

Status: Ongoing
Study area: Neurology
Principal investigator: Laurie Mischley, ND
Project period: January 2010 – December 2014
Parkinson's disease (PD) is considered a progressive and irreversible neurodegenerative disease. Current therapies improve disease symptoms, however none alter the underlying degenerative course.